Agios Pharmaceuticals, Inc.
AGIO
$33.52
$0.932.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 259.25% | 137.75% | 86.09% | 43.69% | 44.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 259.25% | 137.75% | 86.09% | 43.69% | 44.57% |
| Cost of Revenue | 10.79% | 11.70% | 6.98% | 20.80% | 18.69% |
| Gross Profit | 27.32% | 5.19% | 4.60% | -17.61% | -15.52% |
| SG&A Expenses | 12.38% | 16.32% | -0.17% | 7.10% | 29.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.32% | 13.36% | 4.26% | 16.08% | 21.92% |
| Operating Income | 12.99% | -3.18% | 2.77% | -13.67% | -20.07% |
| Income Before Tax | 10.10% | -11.00% | -3.47% | -110.33% | -16.54% |
| Income Tax Expenses | -- | -- | 88.55% | -- | -- |
| Earnings from Continuing Operations | 10.10% | -11.00% | -11.93% | -110.91% | -16.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.10% | -11.00% | -11.93% | -110.91% | -16.54% |
| EBIT | 12.99% | -3.18% | 2.77% | -13.67% | -20.07% |
| EBITDA | 13.19% | -3.14% | 2.72% | -13.83% | -20.70% |
| EPS Basic | 12.45% | -8.50% | -9.54% | -110.69% | -14.27% |
| Normalized Basic EPS | 12.45% | -8.50% | -1.26% | -14.98% | -14.27% |
| EPS Diluted | 12.45% | -8.50% | -9.54% | -110.97% | -14.27% |
| Normalized Diluted EPS | 12.45% | -8.50% | -1.26% | -18.00% | -14.27% |
| Average Basic Shares Outstanding | 2.69% | 2.30% | 2.19% | 2.11% | 1.99% |
| Average Diluted Shares Outstanding | 2.69% | 2.30% | 2.19% | -0.50% | 1.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |